Matthew S. Davids provides insights into the potential of the new drug class of protein degraders in CLL treatment and discusses recently identified biomarkers that are prognostic or predictive in the era of targeted therapy. He also evaluates the performance of BTK-inhibitor-based treatments in high-risk CLL or after prior exposure to targeted agents and explores strategies to overcome real-world barriers to guideline- and evidence-based care in CLL.

John Seymour elucidates the promising outcomes of BTK degraders in hematological malignancies, as for example demonstrated in the CaDAnCe-101 trial, and reflects on their future role in treatment strategies. He delves into the pros and cons of fixed-duration versus continuous therapy in CLL and highlights the clinical significance of clonal hematopoiesis in patients with CLL.

Diego Kauffmann-Guerrero provides insights into bispecific antibody treatments, an emerging class of therapeutics for small-cell lung cancer and neuroendocrine tumors of the lung. He highlights trials involving BiTEs in combination with other agents and offers an outlook on new treatment options for small-cell lung cancer expected to emerge in the coming years.

Gerrina Ruiter dives into the exciting world of HER2, exploring why it poses a tricky challenge in treating NSCLC, highlights the promising findings of the HER2 tyrosine kinase inhibitor zongertinib and shares insights on other notable innovations on the horizon in the field of HER2 inhibition.